A5029533765- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Venous Thromboembolism Diagnosis and Management
- Cardiac electrophysiology and arrhythmias
- Cardiac Imaging and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
- Acute Ischemic Stroke Management
- Acute Myocardial Infarction Research
- Heart Failure Treatment and Management
- Blood Pressure and Hypertension Studies
- Coronary Interventions and Diagnostics
- Lipoproteins and Cardiovascular Health
- Blood Coagulation and Thrombosis Mechanisms
- Cardiac pacing and defibrillation studies
- Cerebrovascular and Carotid Artery Diseases
- Cardiac tumors and thrombi
- Cardiac Fibrosis and Remodeling
- Cardiovascular Function and Risk Factors
- Vitamin K Research Studies
- Pharmacogenetics and Drug Metabolism
- Pharmaceutical Economics and Policy
- GDF15 and Related Biomarkers
- Cardiac Valve Diseases and Treatments
- Pharmaceutical industry and healthcare
Lankenau Institute for Medical Research
2015-2024
Thomas Jefferson University
2015-2024
Bryn Mawr Hospital
2017-2024
Lankenau Medical Center
2015-2024
Jefferson College
2013-2023
Main Line Health
2008-2022
Lankenau Heart Institute
2011-2022
Duke University
1997-2022
Sidney Kimmel Cancer Center
2017-2021
University of Utah
2019-2020
Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases hemorrhage and is difficult to use. Dabigatran a new oral direct thrombin inhibitor.
The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention future stroke among survivors ischemic or transient attack. addressed all clinicians who manage secondary for these patients. Evidence-based are provided control risk factors, intervention vascular obstruction, antithrombotic therapy cardioembolism, antiplatelet noncardioembolic stroke. Recommendations also recurrent in a variety specific circumstances, including aortic...
Cardiovascular disease (CVD) is the leading cause of death in United States and responsible for 17% national health expenditures. As population ages, these costs are expected to increase substantially.To prepare future cardiovascular care needs, American Heart Association developed methodology project hypertension, coronary heart disease, failure, stroke, all other CVD from 2010 2030. This avoided double counting patients with multiple conditions. By 2030, 40.5% US projected have some form...
The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial.In this double-blind, placebo-controlled trial, we randomly assigned 665 who were receiving anticoagulants had persistent receive amiodarone (267 patients), sotalol (261 or placebo (137 patients) monitored them for 1 4.5 years. primary end point was the time recurrence of beginning on day 28, determined by weekly transtelephonic monitoring.Spontaneous conversion...
Dabigatran reduces ischemic stroke in comparison with warfarin; however, given the lack of antidote, there is concern that it might increase bleeding when surgery or invasive procedures are required.The current analysis was undertaken to compare periprocedural risk patients Randomized Evaluation Long-Term Anticoagulation Therapy (RE-LY) trial treated dabigatran and warfarin. Bleeding rates were evaluated from 7 days before until 30 after procedures, considering only first procedure for each...
The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 (D150) with warfarin for stroke prevention in 18 113 patients nonvalvular atrial fibrillation.Cardioversion on randomized treatment was permitted. Precardioversion transesophageal echocardiography encouraged, particularly dabigatran-assigned patients. Data from before, during, 30 days after cardioversion were analyzed. A total 1983 cardioversions performed 1270 patients:...
The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial showed that dabigatran etexilate 150 mg BID was superior and 110 noninferior to warfarin in preventing stroke systemic embolism patients with atrial fibrillation. In this subgroup analysis, we assess the efficacy safety who did not receive concomitant antiplatelets.All comparisons used a Cox proportional hazards model adjustments made for risk factors bleeding. A time-dependent analysis performed when comparing...
Background— Chronic heart failure remains a major cause of mortality and morbidity. The role antithrombotic therapy in patients with chronic has long been debated. objective this study was to determine the optimal agent for reduced ejection fractions who are sinus rhythm. Methods Results— This prospective, randomized clinical trial open-label warfarin (target international normalized ratio 2.5 3.0) double-blind treatment either aspirin (162 mg once daily) or clopidogrel (75 had 30-month...